CClinicalTrials.gg
CompletedNCT01053598NRA RETAUpdated Feb 20, 2013

Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting

An observational study in Tuberculosis, HIV and AIDS, sponsored by Epicentre. Completed at 1 site in Uganda. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2013-02-20.

Sponsored by Epicentre · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
14 Years and older
Sex
All
01

Study summary

The Principle objective of this study is To evaluate the performance of NRA, NRA-p and REMA-p for the detection of M. tuberculosis complex from sputum samples from adult pulmonary TB suspects in a high TB and HIV prevalence setting, using LJ and MGIT culture as gold standard.

The Secondary objectives are:

  • To measure the performance of each assay (NRA, NRA-p, REMA-p) in sputum smear-negative patients
  • To describe the results of the colorimetric methods in HIV-positive and HIV-negative patients
  • To assess the time to detection of both NRA/NRA-p, REMA-p methods.
  • To evaluate the feasibility of the NRA, NRA-p, REMA-p methods.
  • To determine the rate of contamination of the NRA, NRA-p and REMA-p assays.
  • To evaluate the proportion and the clinical relevance of NTM among TB suspects in a high TB and HIV prevalence setting.
  • To provide capacity building for TB diagnosis in Mbarara.
Read the detailed description

Tuberculosis (TB) remains a leading cause of death in developing countries and its burden has been exacerbated by the concurrent HIV epidemic. Despite the advances in medicine, TB diagnosis still remains a challenge, especially in developing countries where diagnosis relies mostly on the detection of Mycobacterium tuberculosis complex (MTBC) by smear microscopy and/or culture. Smear microscopy is rapid, simple and not expensive but it lacks sensitivity. Culture on solid medium, which is performed in some well equipped laboratories, is more sensitive than microscopy but takes up to 8 weeks to obtain the result.

Colorimetric methods have been used for the rapid detection of drug sensitivity in M. tuberculosis either from isolates or directly from sputum. These methods rely on the detection of live bacteria through either enzymatic activity (nitrate reduction) or their ability to reduce an oxidation-reduction indicator, either in solid or liquid medium. They are fast, simple, and offer a good potential that should be evaluated for the diagnosis of TB.

The objective of this study is to evaluate the performance of colorimetric assays for the detection of M. tuberculosis complex from sputum samples from adult pulmonary TB suspects in a high TB and HIV prevalence setting, using Löwenstein Jensen (LJ) and Mycobacterium growth indicator tube (MGIT) culture as gold standard. The colorimetric methods evaluated here will be the solid medium-based nitrate reductase assay as described (NRA) or with an additional step using para Nitrobenzoic (PNB) acid for differentiation of MTBC and NTM (NRA-p), and the modified resazurin microplate assay, also using PNB for differentiation of MTBC and NTM (REMA-p).

. If any of the colorimetric assays is found to be accurate, significantly faster than conventional culture methods, and easy to perform, then it could be implemented in a tuberculosis culture laboratory. By reducing the time to detection compared to conventional culture and the costs compared to recent commercial methods, these assays offer a good alternative to conventional methods and might help to improve TB diagnosis in developing countries.

02

Conditions studied

  • Tuberculosis
  • HIV
  • AIDS
  • HIV Infections

Keywords

  • Mycobacterium tuberculosis
  • Nitrate Reductase Assay
  • NRA
  • REMA
  • RETA
  • Rezazurine
03

In context

Tuberculosis

1,417 studies on the registry are indexed under Tuberculosis; 208 are open to participants now.

This study's planned enrollment of 600 is above the median of 250 across 421 observational studies indexed under Tuberculosis.

Browse Tuberculosis studies →

Lead sponsor

Epicentre is the lead sponsor of 47 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients presenting at the outpatient department of the MRRH will be eligible if they meet the inclusion criteria

Inclusion criteria

  • Pulmonary TB suspects as defined by a cough for more than 2 weeks
  • Age 15 years and above
  • Written informed consent signed

Exclusion criteria

Exclusion Criteria:

  • Producing pure blood sputum or clear saliva
  • Producing less than 1 mL of sputum
  • Receiving anti TB treatment (isoniazid, rifampicin, streptomycin, pyrazinamide, ethambutol) or quinolone for more than 1 week in the month before inclusion.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
06

What researchers measure

Primary outcomes

  1. To evaluate the performance of NRA, NRA-p and REMA-p for the detection of M. tuberculosis complex from sputum samples from adult pulmonary TB suspects in a high TB and HIV prevalence setting, using LJ and MGIT culture as gold standard

    Time frame: 7 Month

Secondary outcomes

  1. -To measure the performance of each assay (NRA, NRA-p, REMA-p) in sputum smear-negative patients -To describe the results of the colorimetric methods in HIV-positive and HIV-negative patients

    Time frame: 7 Month

07

Study locations

1 site
  • Epicentre
    Mbarara, 1956, Uganda
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01053598
Lead sponsor
Epicentre
Collaborators
Mbarara University of Science and Technology, Medecins Sans Frontieres, Netherlands
Responsible party
Sponsor
First posted
Jan 21, 2010
Start date
Sep 2011
Primary completion
Sep 2012
Completion
Dec 2012
Last update
Feb 20, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion